LOS ANGELES, March 16, 2018, /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr Eric Curtis, Advisor to the Chairman and CEO, will present at the 28th Annual Oppenheimer Healthcare Conference on Wednesday, March 21, 2018 at 3:55 P.M. Eastern Daylight Time at the Westin New York Grand Central in New York, New York.
During July last year the company announced their strategic agreement with Nantcell.inc and the stock moved that day for about 48 % gain.Since that, CYTR stock shifted away from the uptrend road. The reverse split took place on the first of Nov 2017, and this also doubled down the stock price. Since the end of last Feb, the stock has started to gain some bullish momentum. With possible some good news ahead for their LADR™ (Linker Activated Drug Release ) this stock might turn some investors eye on it.
Our rate for this stock is Buy / strong hold for the next 30 days with possible 3.25 $ price target.
If you would like to know more about a possible good price entry and other info please join our mail list .
Important note: We are just a small team of independent traders and uncertified technical chart analysis, and we do not have any insider trading or connection with any company related to any stocks we mentioned. You own your decision to buy, hold or sell any of them.
DISCLAIMER: As an investor, you know that any kind of investment opportunity has its risks. There is no such thing as low risk stocks and we recommend you invest wisely. Investing in Stocks is highly speculative. All of the content on our website and in our email alerts is for informational purposes only, and should not be construed as an offer, or solicitation of an offer, to buy or sell securities.
Share on Facebook
Share on Twitter
I'm busy working on my blog posts. Watch this space!